Calibrate IV Hydration Warned by FDA Over Stem Cell and Exosome Treatments

The Food and Drug Administration (FDA) has issued a warning letter to Calibrate IV Hydration concerning its marketing and sale of umbilical cord-derived stem cell products and exosome infusions. The October 13, 2026, letter raises questions about the regulatory status of regenerative medicine treatments being marketed to consumers seeking alternatives for inflammation, injury recovery, and other health concerns.

According to the FDA, the agency reviewed Calibrate IV Hydration's website and determined that the company's umbilical cord-derived and exosome products were being marketed as unapproved new drugs and unlicensed biological products. The warning was issued by the FDA's Center for Biologics Evaluation and Research and addressed to the company's medical director, Dr. Neville Campbell.

What the FDA Found

The FDA cited several statements on Calibrate's website describing potential benefits of its stem cell and exosome IV treatments. These included claims concerning neurological health, immune function, joint and tissue repair, inflammation management, hormonal balance, and skin regeneration.

The agency concluded that the products were intended to diagnose, treat, mitigate, or prevent disease, or affect the structure or function of the human body. Based on those intended uses, the FDA determined that the products required regulatory authorization that had not been obtained.

The warning letter specifically addresses federal drug and biologics requirements. It does not constitute a court judgment or a finding that individual consumers were financially harmed.

Exosome Therapy Marketing and Consumer Questions

Calibrate's educational materials describe exosomes as microscopic particles involved in communication between cells. The company's website identifies its exosomes as being derived from Wharton's Jelly mesenchymal stem cells found in umbilical cord tissue. Its materials discuss potential applications involving tissue repair, inflammation, joint health, neurological conditions, and skin health.

The FDA's regulatory position is important for consumers evaluating these treatments. The agency has stated that there are currently no FDA-approved exosome products. Its warning also highlights the distinction between promising areas of scientific research and treatments that have completed the regulatory review required for marketing.

Medical Daily's reporting on the warning letter further discusses the regulatory questions surrounding regenerative medicine and the importance of understanding what evidence supports advertised treatment benefits.

For consumers, questions may arise when marketing materials describe potential medical benefits without clearly explaining a product's regulatory status or the limitations of existing research. Whether particular advertising statements are misleading under consumer-protection laws depends on the specific representations and applicable legal standards. Calibrate clients can contact our attorneys to discuss further.

Questions About Stem Cell and Exosome Treatment Advertising?

The FDA's warning brings renewed attention to the marketing of stem cell and exosome therapies and the information consumers receive before purchasing these treatments.

The Lyon Firm investigates potential consumer protection claims involving stem cell treatments and allegedly misleading medical advertising. Individuals who purchased regenerative medicine treatments based on representations about their effectiveness and medical benefits may wish to have those representations independently reviewed.

If you have questions about a stem cell or exosome treatment you purchased, contact The Lyon Firm for information about your potential legal options.